Trial · NCT03512197
Results by group181
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 181
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event Free Survival (EFS) | Midostaurin + Chemotherapy | 5.98 | 95% Confidence Interval 2.33 to 8.97 | Months | |
| Event Free Survival (EFS) | Placebo + Chemotherapy | 5.88 | 95% Confidence Interval 3.65 to 7.52 | Months | |
| Overall Survival (OS) (Key Secondary) | Midostaurin + Chemotherapy | NA | 95% Confidence Interval 15.54 to NA | Months | |
| Overall Survival (OS) (Key Secondary) | Placebo + Chemotherapy | 19.22 | 95% Confidence Interval 13.8 to NA | Months | |
| Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Hematological Recovery (CRi) But With Adequate Blood Count Recovery Rate. | Midostaurin + Chemotherapy | 59.2 | 95% Confidence Interval 52.8 to 65.4 | Percentage of participants | |
| Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Hematological Recovery (CRi) But With Adequate Blood Count Recovery Rate. | Placebo + Chemotherapy | 61.0 | 95% Confidence Interval 54.6 to 67.0 | Percentage of participants | |
| Percentage of Participants With Minimal Residual Disease (MRD) Negative Status | Midostaurin + Chemotherapy | 40.8 | Percentage of participants | ||
| Percentage of Participants With Minimal Residual Disease (MRD) Negative Status | Placebo + Chemotherapy | 41.0 | Percentage of participants | ||
| Percentage of Participants With Minimal Residual Disease (MRD) Negative Status During Post-consolidation Phase | Midostaurin + Chemotherapy | 33.3 | Percentage of participants | ||
| Percentage of Participants With Minimal Residual Disease (MRD) Negative Status During Post-consolidation Phase | Placebo + Chemotherapy | 33.3 | Percentage of participants | ||
| Time to Measurable Residual Disease (MRD) Negativity by Flow Cytometry | Midostaurin + Chemotherapy | 2.27 | 95% Confidence Interval 1.61 to 5.68 | Days | |
| Time to Measurable Residual Disease (MRD) Negativity by Flow Cytometry | Placebo + Chemotherapy | 2.07 | 95% Confidence Interval 1.68 to 6.80 | Days | |
| Disease-free Survival (DFS) | Midostaurin + Chemotherapy | 10.5 | 95% Confidence Interval 7.59 to NA | Months | |
| Disease-free Survival (DFS) | Placebo + Chemotherapy | 9.1 | 95% Confidence Interval 6.87 to 12.02 | Months | |
| Cumulative Incidence of Relapse (CIR) | Midostaurin + Chemotherapy | 5.1 | 95% Confidence Interval 2.83 to 7.56 | Months | |
| Cumulative Incidence of Relapse (CIR) | Placebo + Chemotherapy | 6.6 | 95% Confidence Interval 4.99 to 8.77 | Months | |
| Cumulative Incidence of Death (CID) | Midostaurin + Chemotherapy | NA | 95% Confidence Interval 18.00 to NA | Months | |
| Cumulative Incidence of Death (CID) | Placebo + Chemotherapy | NA | 95% Confidence Interval 14.42 to NA | Months | |
| Time to CR or CRi With Adequate Blood Count Recovery | Midostaurin + Chemotherapy | 1.12 | 95% Confidence Interval 1.02 to 1.41 | Days | |
| Time to CR or CRi With Adequate Blood Count Recovery | Placebo + Chemotherapy | 1.15 | 95% Confidence Interval 1.05 to 1.54 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03512197/results